HBV Basic Science
EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Hepatitis B Therapeutic Vaccine Appears Safe and Stimulates Immune Response
- Details
- Category: HBV Vaccines
- Published on Tuesday, 11 January 2011 03:25
- Written by Dynavax
In late December, Dynavax Technologies reported findings from a small early clinical trial showing that its investigational hepatitis B virus (HBV) therapeutic vaccine DV-601 -- intended to help control the virus in people already infected, rather than prevent infection -- was well tolerated and produced immunological and virological responses at all dose levels. Larger studies are needed, however, to show whether the vaccine is clinically effective.
Androgens Promote Hepatitis B Virus Replication, Helping Explain Sex Differences
- Details
- Category: HBV Basic Science
- Published on Tuesday, 21 February 2012 00:00
- Written by Liz Highleyman
The hepatitis B virus (HBV) carries receptors for androgens -- male hormones such as testosterone -- which may help explain why men are more likely than women to develop chronic hepatitis B and experience more aggressive liver disease, according to study findings reported in the February 2012 Journal of Virology.
Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 08 June 2010 12:49
- Written by Liz Highleyman
Interaction between hepatitis B virus (HBV) and the androgen receptor in the liver promotes viral replication and triggers cell changes that lead to development of hepatocellular carcinoma, according to a study in mice described in the May 19, 2010 issue of Science Translational Medicine. Since men have more active androgen receptors than women, these findings help explain why men with hepatitis B are more prone to liver cancer, and suggest that blocking androgen receptors in the liver might be an effective treatment.
Web Design and Development by